CAN-2409 Plus Radiotherapy for Localized Prostate Cancer in a Phase III Trial, Journal Club - Rashid Sayyid & Zachary Klaassen
Zachary Klaassen
Rashid Sayyid and Zachary Klaassen review the phase 3 CAN-2409 trial of aglatimagene besadenovec plus valacyclovir added to radiotherapy in 750 intermediate or high-risk localized prostate cancer patients across 51 US centers.
Radiopharmaceuticals in Prostate Cancer Part 3A: Patient Selection and Treatment Sequencing - Tanya Dorff, Neal Shore & Dustin Boothe
Tanya Dorff
Tanya Dorff, Neal Shore, and Dustin Boothe discuss patient selection and treatment sequencing for lutetium-177 PSMA across the pre- and post-chemotherapy mCRPC settings.
